Heerajnarain Bulluck, Jun Hua Chong, Jennifer Bryant, Annitha Annathurai, Ping Chai, Mervyn Chan, Ashish Chawla, Chee Yang Chin, Yiu-Cho Chung, Fei Gao, Hee Hwa Ho, Andrew Fu Wah Ho, John Hoe, Syed Saqib Imran, Chi-Hang Lee, Benji Lim, Soo Teik Lim, Swee Han Lim, Boon Wah Liew, Patrick Lim Zhan Yun, Marcus Eng Hock Ong, Valeria Paradies, Xuan Ming Pung, Julian Cheong Kiat Tay, Lynette Teo, Boon Ping Ting, Aaron Wong, Evelyn Wong, Timothy Watson, Mark Y Chan, Yeo Khung Keong, Jack W C Tan, Derek J Hausenloy
Background: The administration of intravenous cangrelor at reperfusion achieves faster onset of platelet P2Y12 inhibition than oral ticagrelor and has been shown to reduce myocardial infarct (MI) size in the pre-clinical setting. We hypothesized that the administration of cangrelor at reperfusion will reduce MI size and prevent microvascular obstruction (MVO) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods: This was a Phase 2, multi-center, randomized, double-blind, placebo controlled clinical trial conducted between November 2017 to November 2021 in six cardiac centers in Singapore (NCT03102723)...
May 14, 2024: Circulation